top of page

News: New trial of mRNA Vaccines for HIV

The NIH has announced its launching of Phase 1 clinical trial of three experimental mRNA vaccines for HIV.

The exploration comes on the tails of the successful development of several Covid-19 vaccines using the same mRNA technology (i.e., the Pfizer and Moderna vaccines).

The HIV vaccine has been something of a white whale to the clinical research industry, but the NIH hopes it will now be able to create a vaccine that prevents the onset of serious symptoms for the virus.

An mRNA vaccine works by teaching the immune system to recognize a target pathogen through a piece of its genetic material -- rather than through a deactivated piece of the virus, as is the case for other inoculations. Like the two mRNA Covid-19 vaccines, the three experimental HIV vaccines will work by presenting the spike protein found on HIV.

The trial will involve six randomly assigned groups, wherein each participant will receive three doses of their assigned vaccine candidate. The first wave will involve three groups each receiving 100µg of their respective vaccine upon arrival, then at two months and six months after the trial begins. If the safety profile is deemed acceptable, the next group will receive 250µg doses of their assigned vaccines following the same schedule.

Want to Learn More?

In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient perspective should be considered when designing studies to ensure that patient targets are met not only on time but also on budget.

For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real-time. The best part: these patients are already educated and prepared for the clinical trial process.

If you’d like to hear more about what we do, go here to read about what sets us apart, or hereto read what our patients have to say about us.


bottom of page